RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.

Regulatory Focus™ > News Articles > In Focus: Risk Management of Medical Products

In Focus: Risk Management of Medical Products

Posted 01 July 2010 | By

In this issue of Regulatory Focus we explore current practices for managing the risks of medical products. The US Food and Drug Administration (FDA) and its counterparts around the world are responsible for protecting public health by ensuring the safety and effectiveness of drugs and devices. To achieve this mission, regulators must decide whether a given product's benefits to patients and users outweigh its risks, while recognizing that "absolute safety" is not achievable.

Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe

Regulatory Focus™ is doing essential, non-biased journalism during this unprecedented time. We appreciate your support as we bring you the news and intelligence you need to make an impact on global healthcare.

Regulatory Focus™ provides the intelligence you need to impact global healthcare during this crisis. Thank you for your support.